abbv-383
mAbexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Mar 24, 2022 (NCT05286229)
Timeline
Indications
Mechanism of action
CD3E
- BCMABINDING AGENT
BCMA
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314973 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07095452 | Phase 2/Phase 3 (Phase 3) | Nov 12, 2025 | AbbVie, Program for the Study and Treatment of Haematological Malignances |
| NCT06896916 | Phase 1 | Aug 7, 2025 | AbbVie |
| NCT06892522 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | AbbVie |
| NCT06223516 | Phase 1 | Jun 17, 2024 | AbbVie |
| NCT06158841 | Phase 3 | Apr 26, 2024 | AbbVie |
| NCT06158854 | Phase 1 | Mar 27, 2024 | AbbVie |
| NCT05650632 | Phase 1 | Apr 1, 2023 | Teneobio, Inc. |
| NCT05259839 | Phase 1 | Oct 20, 2022 | Teneobio, Inc. |
| NCT05286229 | Phase 1 | Mar 24, 2022 | AbbVie |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 7 | 7 | 3 | 2022 |
| Teneobio, Inc. | For profit | 2 | 2 | 1 | 2022 |
| Program for the Study and Treatment of Haematological Malignances | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1